Pain Channel
Topics & Medications
Quicklinks
Related Channels

Effects of Darvon

In November 2010, the United States Food and Drug Administration (FDA) withdrew all medications that contain propoxyphene from the market. It has been determined that the risks of propoxyphene outweigh the possible benefits. In particular, the FDA was concerned about the drug's ability to cause serious changes in the heart rhythm, even at normal doses. Pharmacies will no longer sell this medication, and people who take it should stop and ask their healthcare provider for a more suitable pain medication.
 
Darvon® (propoxyphene hydrochloride) is a prescription drug licensed to treat mild-to-moderate pain in adults.
 
As a centrally acting narcotic pain reliever, Darvon works in the central nervous system (the brain and spinal cord), rather than directly at the site of the pain. The effects of Darvon are not considered as "strong" as those of most other narcotic pain relievers. Because it is a weaker painkiller and can be potentially lethal in the case of an overdose, Darvon is not usually a "first choice" pain medication in most situations.
 
Darvon's effects can also cause psychological and physical dependence. This medication is a narcotic drug and is classified as a controlled substance. Although there are strict rules and regulations regarding its sale and use, this is a commonly abused drug.
 
(Click Darvon for more information on the effects of this drug. This article provides detail on how this pain medication works, general dosing guidelines, potential side effects, and other important information.)
 
Ways to Prep Your Kitchen to Eat Well During Cancer Treatment
Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.